News & Updates

Treatment with remdesivir in patients hospitalized for COVID-19 does not appear to confer increased risks of acute kidney and liver injury, with a recent study showing that these risks are already elevated even before exposure to treatment and there is no further increase following remdesivir initiation.

Early administration (ie, within 5 days after symptom onset) of the oral, small-molecule antiviral prodrug molnupiravir slashed the risk of hospitalization or death in at-risk, unvaccinated, nonhospitalized adults with mild-to-moderate COVID-19, findings from the phase III component of the phase II/III MOVe-OUT trial have shown.

SARS-CoV-2 infection during pregnancy or the postpartum period is tied to an increased risk of maternal mortality or serious morbidity due to obstetric complications, a study from the US showed.

Anaphylactic reactions warranting treatment after receipt of COVID-19 mRNA vaccinations appear to be relatively rare, according to a US study presented at AAAAI 2022.

Patients with idiopathic pulmonary fibrosis (IPF) exhibit a similar course of lung injury with those having other forms of progressive fibrosing interstitial lung disease (ILD), reveals a study, which also shows the association of forced vital capacity (FVC) decline with short-term mortality in this population.

Smoking and chronic obstructive pulmonary disease (COPD) worsen the risk of postoperative pulmonary complications after lung cancer resection, a recent study has found. Focusing on COPD treatment, rather than smoking cessation alone, may be a more optimal approach to improve postoperative outcomes in this population.